( HS Arms 065685 2025) Hormones and Beyond Addressing Cardiovascular Health & Breast Cancer Risk in Postmenopausal Patients

Course overview

Many providers are stuck navigating outdated research, patient fears, and widespread misinformation when it comes to hormone therapy HT. This session cuts through the confusion to provide a clear, evidence-based path forward. Youll explore the cardiovascular risks that rise with estrogen loss, the timing-dependent benefits of HT, and how to separate fact from fear when discussing breast cancer risk. Well walk through the most misunderstood research like the WHI study and provide tools to translate evolving evidence into confident clinical decision-making. Youll also gain a detailed understanding of HT formulations (oral vs. transdermal, synthetic vs. bioidentical), how to assess your patient for candidacy, and the latest evidence on HT use in survivors of breast cancer. Well round out the session with non-hormonal options like SSRIs, gabapentinoids, and the newly approved fezolinetant and practical prevention strategies grounded in nutrition and lifestyle. Whether youre hesitant to recommend HT or want better tools to communicate risk, this course will help you individualize care, improve outcomes, and empower your patients.